Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.25.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash Flows From Operating Activities    
Net income $ 1,007 $ 3,145
Adjustments to reconcile net income to net cash    
Depreciation and amortization 196 119
Interest accretion expense 30
Amortization of deferred financing fees 26
Stock-based compensation 24 132
Bad debt expense reversal (100)
Credit loss expense 26
Asset impairment - lab supplies 198
Change in fair value of note payable (18) 41
Amortization on operating lease right of use asset 193 229
Other changes in operating assets and liabilities:    
Accounts receivable 1,313 (1,154)
Other current assets (227)
Accounts payable (409) (13)
Accrued salaries and bonus (176) (726)
Other accrued expenses (401) (373)
Operating lease liabilities (185) (188)
Other long-term liabilities 214 178
Net cash provided by operating activities 1,755 1,346
Cash Flows From Investing Activity    
Purchase of property and equipment (201) (225)
Net cash used in investing activities (201) (225)
Cash Flows From Financing Activities    
Payments made on note payable (2,500) (2,600)
Series C conversion costs (13)
Net cash used in financing activities (2,513) (2,600)
Net decrease in cash and cash equivalents (959) (1,479)
Cash and cash equivalents from continuing operations– beginning 1,461 3,498
Cash and cash equivalents from discontinued operations– beginning
Cash and cash equivalents – beginning 1,461 3,498
Cash and cash equivalents from continuing operations– ending 502 2,019
Cash and cash equivalents from discontinued operations– ending
Cash and cash equivalents – ending $ 502 $ 2,019